Eskander, R. N., Lee, J., Mirza, M. R., Lorusso, D., Mackay, H., Ray-Coquard, I. L., Oaknin, A., Martin, A. G., Hasegawa, K., Corr, B., Wu, X., Leary, A., Hu, T., Dutta, L., Okpara, C. E., McKenzie, J., Makker, V. (2025). Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians’ choice in advanced/recurrent endometrial carcinoma previously treated with anti–PD-(L)1 immunotherapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps5632